Clinical Trial Update: Efficacy and Safety Study of CD2027 Ointment 3 Microgram Per Gram (mcg/g) Twice Daily Treatment for Adults With at Least Moderate Atopic Dermatitis [Phase 2]

View source ↗

Summary

Phase 2 trial update for CD2027 ointment shows efficacy and safety data in adults with at least moderate atopic dermatitis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis

Drugs mentioned

• CD2027

Snippet

Sponsor: Galderma R&D | Conditions: Atopic Dermatitis | Phase 2 | Status: COMPLETED | Results posted: 2012-05-01